Physician profile
Tara L Cuda
NPI 1770532293
$19,268.83
in general payments reported to CMS, 2019-2025
46 companies · $2,685 in 2025
The $2,685 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,758 · 2020: $4,346 · 2021: $2,145 · 2022: $2,369 · 2023: $2,778 · 2024: $3,187 · 2025: $2,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,933 · Consulting Fee: $675 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,933.37 |
| Consulting Fee | $675.00 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,105.79 | 2019-2020 | |
| Abbvie INC. | $2,248.55 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Astrazeneca Pharmaceuticals LP | $1,854.70 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,466.61 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,364.73 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $993.63 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $962.27 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $958.65 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $610.80 | 2020-2025 | Xifaxan |
| Amarin Pharma, INC. | $561.07 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $554.04 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $496.91 | 2019-2024 | Xarelto |
| Amgen INC. | $419.14 | 2019-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $417.73 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $397.19 | 2019-2024 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Cuda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.